Drug intelligence / Profile preview

PMC-901

Development stage: Preclinical
Lead developer: PharmAbcine
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PMC-901 is a bevacizumab biosimilar currently in preclinical development by PharmAbcine. It is a monoclonal antibody designed to target and neutralize vascular endothelial growth factor A (VEGF-A), a key mediator of angiogenesis in tumors and certain eye diseases. PMC-901 is developed using a high-productivity cell line with a titer of 3g/L, which is reported to be higher than that of the originator product, Avastin. As a biosimilar, it aims to provide a highly similar therapeutic profile to bevacizumab for the treatment of various solid tumors and potentially ophthalmic conditions.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on PMC-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMC-901.

Explore the full profile